San Diego-based Amylin Pharmaceuticals (NASDAQ: [[ticker:AMLN]]), along with partners Eli Lilly and Waltham, MA-based Alkermes (NASDAQ: [[ticker:ALKS]]), said today that the FDA deadline for reviewing a once-weekly injectable diabetes drug has been pushed back one week, to March 12, because of the mid-Atlantic snowstorm earlier this month. If approved, analysts expect the drug, exenatide once-weekly, will become a blockbuster seller as the first diabetes treatment that can be taken with less frequent, once-weekly injections.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
